Single steroid-free psoriasis foam treats both scalp and body

Once relegated to the backstage of beauty routines, the scalp invites itself today to the head to post capillary rituals.

Single steroid-free psoriasis foam treats both scalp and body

A recent Phase 3 clinical trial demonstrated that a steroid-free topical foam, roflumilast (Zoryve), significantly improved the signs and symptoms of psoriasis on both the scalp and body. The foam treatment, which targets inflammation and reduces itching, offers a unified approach to treating psoriasis, eliminating the need for separate prescriptions for different body areas. With promising results and minimal adverse events, roflumilast foam co…

Roflumilast Foam 0.3% for Scalp, Body Psoriasis Effective, Safe for Patients

These phase 3 findings from the ARRECTOR trial, published in JAMA, demonstrate rapid and significant relief from plaque psoriasis with roflumilast foam use.

Roflumilast Foam Showed Strong Results for Scalp and Body Psoriasis in Teens and Adults

A new JAMA Dermatology study found that once-daily Zoryve (roflumilast) foam, 0.3%, safely and effectively reduced scalp and body plaque psoriasis symptoms in patients 12 and older, offering a convenient, and more tolerated treatment option that may boost adherence and quality of life.

Phase 3 Trial Confirms Roflumilast’s Dual-Site Efficacy

Roflumilast foam shows significant efficacy in treating scalp and body psoriasis, enhancing patient adherence and quality of life in a recent clinical trial.

Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology - Arcutis Biotherapeutics

Once-daily, investigational ZORYVE foam 0.3%, rapidly improved psoriasis of the scalp and body, including itch, when used as a monotherapy 66.4% of individuals treated with ZORYVE foam achieved Scalp-Investigator Global Assessment (S-IGA) Success at Week 8 45.5% of individuals treated with ZORYVE foam achieved Body-Investigator Global Assessment (B-IGA) Success at Week 8 Efficacy and safety results were consistent with Phase 2 results of ZORYVE …